MARKEL GROUP INC.

MKL

Markel Group Inc. engages in the insurance business in the United States, the United Kingdom, Bermuda, Germany, rest of the European Union, Canada, and the Asia Pacific. It operates through Markel Insurance, Industrial, Financial, and Consumer and Other segments.

Country: United StatesPrice: $1847.24Market Cap: $22.9B

Company Profile

Industry: Insurance
SIC Sector: Insurance Carriers
Size: Large Cap($22.9B)
Revenue: $15.5B+4.7% YoY
Net Income: $2.1B-23.3% YoY

Financial Snapshot

Operating Margin20.6%
Return on Equity11.3%
Debt / Equity0.23
Current Ratio--
EPS (Diluted)$169.2215.1%
Buybacks (1y)$429.5M
Buybacks (2y)$1.0B
Shares Retired3.0% / 5.5% 2y

Shareholder Return

Fiscal 2025

Retired 3.0% of shares last year, 5.5% over two.

Buybacks
$429.5M
Dividends

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY24
35.6% = 37.6% + −1.5%
FY25
−15.1% = −23.3% + 10.7%
Earnings Fewer shares More shares

The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Annual data (10-K) · Last 5 years

MetricFY 2025FY 2024FY 2023FY 2022FY 2021
Market Cap$22.9B$23.8Best.$20.0Best.$19.1Best.$17.0Best.
Revenue$15.5B5%$14.8B4%$14.3B22%$11.7B9%$12.8B
Operating Income$3.2B14%$3.7B27%$2.9B3238%-$93.3M103%$3.2B
Net Income$2.1B23%$2.7B38%$2.0B1023%-$216.3M109%$2.4B
EPS (Diluted)$169.2215%$199.3236%$146.98720%$-23.72113%$176.38
Gross Margin
Operating Margin20.6%18%25.1%22%20.5%2666%-0.8%103%25.2%
ROE11.3%30%16.2%22%13.3%910%-1.6%110%16.5%
Total Debt$4.3B1%$4.3B15%$3.8B8%$4.1B6%$4.4B
Shareholders' Equity$18.6B10%$16.9B13%$15.0B14%$13.2B11%$14.7B
Current Ratio
Debt / Equity0.2310%0.261%0.2519%0.315%0.30
Operating Cash Flow$2.8B6%$2.6B7%$2.8B3%$2.7B19%$2.3B
Free Cash Flow$2.6B9%$2.3B7%$2.5B3%$2.5B15%$2.1B
Scored from 10-K1d ago
MetricMarks

Risk-Aware Value

Akre

Three-Legged Stool

Druckenmiller

Macro-Enhanced Growth

Spier

Value Checklist

Pabrai

Dhandho Framework

Munger

Quality Focus

Ackman

Activist Value

Piotroski

F-Score

Greenblatt

Magic Formula

Lynch

GARP

Buffett

Quality Compounder

Graham

Defensive Value

VerdictBUYPASSBUYBUYBUYBUYBUYPASSNot rankedBUYHOLDPASS
Score
Analysis
Intrinsic Value
Margin of Safety-36.8%-7.7%+32.2%+32.0%+28.4%+49.3%+45.3%-25.6%+9.8%+56.2%+52.0%+21.9%
Data As Of10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)10-K (2026-08-15)

Where They Agree

  • Cash Flow

    All 6 investors pass MKL's cash flow

    FCF Positive18/18 years FCF positive
    MarksPositive FCF in majority of recent years
    P/E or FCF YieldP/E=12.2x, FCF Yield=9.7%
    PabraiP/E < 15 or FCF Yield > 10%
    (OCF - CapEx) / Market Cap9.7%
    Ackman>= 4%
    Price / FCF per Share10.3x
    Ackman<= 25
    Show 4 more metrics
    Operating Cash Flow$2.8B
    PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=4.01%, ROA=3.06%
    PiotroskiCFO/Assets > ROA
    FCF Positive and Growing$2.6B
    LynchPositive and growing
    Free Cash Flow Proxy$2.0B
    BuffettPositive and growing

Where They Disagree

  • Profitability

    2 of 11 pass — Marks, Akre, Druckenmiller +6 more object

    Discount to Intrinsic Value19.6% (IV=$2577.60 vs Price=$2072.47)
    Marks>= 20% below intrinsic value
    Positive Net Income Frequency30/33 years positive
    MarksPositive net income in >= 7 of last 10 years
    Return on Equity13.6% (3-yr avg)
    AkreROE > 20% (3-year avg)
    EPS Growth AccelerationLatest: -15.1%, Prior: 35.6%
    DruckenmillerAccelerating EPS growth
    Show 19 more metrics
    Margin of SafetyP/E=12.2x, P/B=1.4x
    SpierP/E < 15 AND P/B < 2.0PabraiP/B < 1.5 or P/E < 15
    Operating Income / Revenue20.6%
    Ackman>= 15%
    Net Income / Shareholders Equity11.3%
    Ackman>= 15%
    Net Income / Total Assets3.06%
    PiotroskiROA > 0
    ROA Change YoY4.44% -> 3.06% (delta: -1.38%)
    PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=4.01%, ROA=3.06%
    PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY
    PiotroskiImproved YoY
    EBIT / Enterprise Value12.0%
    Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=12.0%, ROC=None
    GreenblattBoth EY > 10% and ROC > 25%
    3-5 Year EPS CAGR24.9%
    Lynch15-30% (Fast Grower); > 0% to pass
    ROE11.3%
    Lynch> 15%
    Net Income Positive (10+ years)30/33 years positive
    BuffettPositive every year for 10+ years
    ROE (5-yr avg)11.1%
    Buffett> 15% (5-yr avg)
    Operating Margin (10-yr trend)20.6% (latest)
    BuffettStable or rising over 10 years
    Free Cash Flow Proxy$2.0B
    BuffettPositive and growing
    Earnings Variance (10-yr CoV)1.24
    BuffettCoV < 0.3
    Retained Earnings Effectiveness1.10x
    Buffett$1 retained -> > $1 market value created
    Positive EPS (10 years)21/33 years positive
    GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    Graham>= 33% growth
  • Debt & Leverage

    6 of 8 pass — Lynch and Graham object

    Interest Coverage & Debt/EBITDAIC=15.5x, D/EBITDA=1.3x
    MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Debt Levels0.23
    AkreDebt/Equity < 0.3MungerDebt/Equity < 0.5
    Total Debt / Shareholders Equity0.23
    Ackman<= 1.0
    LT Debt / Total Assets Change7.00% -> 6.25%
    PiotroskiDecreased YoY
    Show 4 more metrics
    Total Debt / Equity0.23
    Lynch< 0.33
    Cash - Long-term Debt$-339.1M
    LynchPositive preferred
    Debt/Equity & Interest CoverageD/E: 0.23, IC: 15.5x
    BuffettD/E < 0.5 AND Interest Coverage > 5x
    LT Debt vs Net Current Assets
    GrahamLT Debt <= Net Current Assets
  • Valuation

    7 of 9 pass — Marks and Greenblatt object

    P/B or P/E vs. Historical AverageP/E=12.2x, P/B=1.4x
    MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value19.6% (IV=$2577.60 vs Price=$2072.47)
    Marks>= 20% below intrinsic value
    Price vs. 200-day MAQualitative
    DruckenmillerPrice above 200-day moving average
    Margin of SafetyP/E=12.2x, P/B=1.4x
    SpierP/E < 15 AND P/B < 2.0
    Show 9 more metrics
    P/E or FCF YieldP/E=12.2x, FCF Yield=9.7%
    PabraiP/E < 15 or FCF Yield > 10%
    Valuation ReasonablenessP/E=12.2x, OE Yield=7.2%
    MungerP/E < 25 or Owner Earnings Yield > 5%
    Price / FCF per Share10.3x
    Ackman<= 25
    EBIT / Enterprise Value12.0%
    Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=12.0%, ROC=None
    GreenblattBoth EY > 10% and ROC > 25%
    P/E / EPS Growth Rate0.49
    Lynch< 1.0 (ideally < 0.5)
    Price / 3-yr avg EPS12.1x
    Graham<= 15x
    Price-to-Book Ratio1.4x
    Graham<= 1.5x
    P/E x P/B17.00
    Graham<= 22.5
  • Growth

    2 of 5 pass — Druckenmiller, Ackman and Graham object

    Positive Net Income Frequency30/33 years positive
    MarksPositive net income in >= 7 of last 10 years
    EPS Growth AccelerationLatest: -15.1%, Prior: 35.6%
    DruckenmillerAccelerating EPS growth
    Revenue Growth RateLatest: 4.7%, Prior: 3.7%
    DruckenmillerRevenue growth accelerating
    3yr Median Revenue Growth4.7%
    Ackman>= 5%
    Show 5 more metrics
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    AckmanPositive EPS growth in >= 3 of last 5 years
    P/E / EPS Growth Rate0.49
    Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR24.9%
    Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -3.8% vs Rev: 4.7%
    LynchInventory growth < Revenue growth
    EPS Growth (3-yr avg, 10-yr window)
    Graham>= 33% growth
  • Efficiency

    1 of 6 pass — Akre, Munger, Piotroski +2 more object

    ROIC (high and growing)0/8 years ROIC > 15% (latest: 11.0%)
    AkreROIC > 15% for 3+ years
    Reinvestment Rate x ROIC11.0% (RR=100% x ROIC=11.0%)
    AkreReinvestment Rate * ROIC > 10%
    Return on Invested Capital11.0%
    Munger> 15%
    Current Ratio Change YoY
    PiotroskiIncreased YoY
    Show 5 more metrics
    Revenue / Total Assets Change YoY0.24x -> 0.23x
    PiotroskiImproved YoY
    EBIT / (NWC + Net Fixed Assets)
    Greenblatt> 25%
    ROIC (3-5 yr avg)12.4%
    Buffett> 10%
    ROIC - WACC+2.4%
    BuffettPositive (WACC = 10%)
    Current Ratio
    Graham>= 2.0
  • Verdicts

    Split decision: 7 BUY · 3 PASS · 1 HOLD

    Overall verdict
    MarksBUY (7/8)AkrePASS (4/7)DruckenmillerBUY (5/7)SpierBUY (8/8)PabraiBUY (7/8)MungerBUY (6/7)AckmanBUY (7/9)PiotroskiPASS (F-Score 5)GreenblattNot rankedLynchBUY (PEG 0.49)BuffettHOLD (6/9)GrahamPASS (4/9)
  • Valuation models

    Models split on MKL at $1847.24 — fair values range $1350.62–$4216.79

    Marks fair value$1350.62
    Marks-36.8% margin vs $1847.24
    Akre fair value$1715.15
    Akre-7.7% margin vs $1847.24
    Druckenmiller fair value$2723.58
    Druckenmiller+32.2% margin vs $1847.24
    Spier fair value$2716.03
    Spier+32.0% margin vs $1847.24
    Show 8 more metrics
    Pabrai fair value$2580.87
    Pabrai+28.4% margin vs $1847.24
    Munger fair value$3645.61
    Munger+49.3% margin vs $1847.24
    Ackman fair value$3374.17
    Ackman+45.3% margin vs $1847.24
    Piotroski fair value$1470.41
    Piotroski-25.6% margin vs $1847.24
    Greenblatt fair value$2047.92
    Greenblatt+9.8% margin vs $1847.24
    Lynch fair value$4216.79
    Lynch+56.2% margin vs $1847.24
    Buffett fair value$3845.04
    Buffett+52.0% margin vs $1847.24
    Graham fair value$2366.12
    Graham+21.9% margin vs $1847.24

Historical Score Timeline

Industry Peers

Similar companies in Insurance

MKL vs Peers — Financial Grading

Revenue$15.5BMedian
Net Income$2.1BMedian
ROE11.3%Median
D/E0.23Median
Op. Margin20.6%Top 25%
Curr. Ratio
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroski
UNITEDHEALTH GROUP INCUNH$360.6B$401.73$447.6B$12.1B12.0%0.784.2%0.793/96/91/70/3F-Score 7
PROGRESSIVE CORP/OH/PGR$121.9B$209.60$87.7B$11.3B37.3%0.003/93/96/70/3F-Score 6
Elevance Health, Inc.ELV$86.8B$400.32$199.1B$5.7B12.9%0.753.6%1.545/95/92/71/3F-Score 6
Cigna GroupCI$74.7B$282.56$274.9B$6.0B14.3%0.013.3%0.851/94/93/71/3F-Score 8
AEGON LTD.AEFC$28.5B$18.36$1.1B10.4%0/91/91/70/3F-Score 5
PRINCIPAL FINANCIAL GROUP INCPFG$24.4B$113.98$15.6B$1.2B10.0%0.332/93/93/70/3F-Score 5
Fidelity National Financial, Inc.FNF$13.3B$49.47$14.4B$602.0M8.1%0.592/92/92/70/3F-Score 5
Enact Holdings, Inc.ACT$6.9B$49.94$1.2B$674.2M12.6%0.145/91/94/70/3F-Score 5